Alaa Halawa is the Head of Healthcare and Executive Director at Mubadala Ventures, the San Francisco-based venture capital division of Mubadala Capital. He focuses on investing in venture and early growth-stage companies in biotechnology, healthcare technology, and healthcare services. Some of Alaa’s notable investments include Recursion (RXRX), Neumora Therapeutics (NMRA), Exscientia (EXAI), Vir Biotechnology (VIR), Altos Labs, Insitro, Innovaccer, Orca Bio, Unlearn, Paradigm, Alloy Therapeutics, Pretzel Therapeutics, Juvena Therapeutics and EpiBiologics. 
Alaa serves on numerous boards, including Neumora Therapeutics, Innovaccer, Pretzel Therapeutics and Alloy Therapeutics. Alaa joined Mubadala in 2009, where he was part of the early team that built Global Foundries, one of the largest semi-conductor manufacturers. Over the course of a decade, he played a pivotal role in transforming Global Foundries into a publicly traded company valued at $30 billion. This journey led him to Silicon Valley in 2011. Subsequently, in 2016, he began building the groundwork for Mubadala Capital's ventures business.
Alaa holds an MBA from Cornell University.